Why Arrowhead Pharmaceuticals, Inc.’s (ARWR) Stock Is Up 20.49%
As of Wednesday, July 22, Arrowhead Pharmaceuticals, Inc.’s ARWR share price has surged by 20.49%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Stock Evaluator: Arrowhead Pharmaceuticals, Inc. (ARWR)
Arrowhead Pharmaceuticals, Inc. ARWR
$84.65
-2.67
-3.06%
July 31, 2026 4:00:00 PM
EST
Volume: 1,657,362
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Commentary & Analysis
Why Arrowhead Pharmaceuticals, Inc.’s (ARWR) Stock Is Up 21.12%
As of Wednesday, July 22, Arrowhead Pharmaceuticals, Inc.’s ARWR share price has surged by 21.12%, which has investors questioning if this is right time to sell.Omar Beirat
Why Arrowhead Pharmaceuticals, Inc.’s (ARWR) Stock Is Down 5.06%
As of Friday, July 10, Arrowhead Pharmaceuticals, Inc.’s ARWR share price has dipped by 5.06%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Arrowhead Pharmaceuticals, Inc.’s (ARWR) Stock Is Up 5.05%
As of Wednesday, June 17, Arrowhead Pharmaceuticals, Inc.’s ARWR share price has surged by 5.05%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Arrowhead Pharmaceuticals, Inc.’s (ARWR) Stock Is Down 7.22%
As of Tuesday, June 02, Arrowhead Pharmaceuticals, Inc.’s ARWR share price has dipped by 7.22%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | ARWR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $12,299.6 | $251.9 | 80% |
|
| Shares Out (Mil) | 142.4 | 50.8 | 70% |
|
| Institutional Ownership | 95.9% | 92.0% | 68% |
|
| Float (Mil) | 122.8 | 40.5 | 65% |
|
| Beta | 1.27 | 0.95 | 74% |
|
| Avg Daily Volume (000s) | 2,641 | 447 | 86% |
|
| Price Change (52-week) |
448.5% | 54.2% | 99% |
|
| Growth | ARWR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 56.6% | 14.0% | 97% |
|
| Net Income (5yr) | 54.8% | (9.8%) | 95% |
|
| EPS (5yr) | 57.2% | 16.3% | 95 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 26.1% | (15.6%) | 84% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 11 | 11 | |
| Current EPS | ($1.232) | ($3.083) | ($4.562) | |
| Month Ago EPS | ($1.202) | ($3.002) | ($4.336) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($1.368) | ($3.425) | ($4.515) | |
| Year/Year Chg | 32.2% | 25,592% | 24,683% | |
| Financials | ARWR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $622 | $39 | 44% |
|
| Net Income (TTM) (Mil) | ($301) | ($43) | 5% |
|
| EPS (TTM) | ($2.163) | ($1.600) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($36) | ($30) | 11% |
|
| Net Cash Flow (TTM) (Mil) | $3 | $3 | 50% |
|
| Long-Term Debt (Q1) (Mil) | $1,326 | $5 | 69% |
|
| Enterprise Value (Q1) (Mil) | $11,810 | $182 | 76% |
|
| Valuation | ARWR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 19.98 | 2.60 | 95% |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ARWR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 63.8% | 96% |
|
| Net Margin | (48.4%) | (64.7%) | 12% |
|
| ROA | (15.7%) | (49.7%) | 22% |
|
| ROE | (46.4%) | (55.4%) | 16% |
|
| Liabilities to Assets | 73.6% | 30.3% | 69% |
|
| F-Score | 2 | 3 | 7% |
|
Arrowhead Pharmaceuticals, Inc. did not pass any screens on 7/30/2026.
